Dark

EXEL
Exelixis Inc
stock NASDAQ

Market Open

Jul 16, 2026 12:59:34 PM EDT

55.64USD+0.162%(+0.09)636,263

53.73Bid 58.77Ask 5.04Spread

Pre-market

Jul 16, 2026 9:28:00 AM EDT

55.53USD-0.036%(-0.02)1,685

After-hours

Jul 15, 2026 4:00:30 PM EDT

55.55USD-0.054%(-0.03)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 18, 2022

05:30PM EST Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022 Business Wire

Jan 10, 2022

08:30AM EST Tenaya Therapeutics Offers 2022 Business Updates Benzinga

05:51AM EST A Peek Into The Markets: US Stock Futures Edge Higher; Crude Oil Up 0.5% Benzinga

Jan 9, 2022

04:53PM EST Exelixis Sees Q4 Revenue ~$300M vs $348.72M Est; Sees FY 2021 Revenue ~$1.08B vs $1.33B Est; Sees FY 2022 Revenue $1.325B to $1.425B vs $1.58B Est Benzinga

04:00PM EST Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022 Business Wire

Jan 6, 2022

08:25AM EST Exelixis And Iconic Therapeutics Amend Option And License Agreement For XB002; Exelixis Gains Full Rights To Use Anti-TF Antibody Incorporated Into XB002 For Any Application, Will Make One-Time Payment Of $55M Benzinga

08:00AM EST Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor Business Wire

Jan 5, 2022

08:17AM EST Exelixis Reports Enrollment Completion In Phase 3 Trial Of Cabozantinib In Combination With Immune Checkpoint Inhibitor RTTNews

08:07AM EST Exelixis Announces Enrollment Completion In Phase 3 CONTACT-03 Pivotal Trial Of Cabozantinib In Combination With An Immune Checkpoint Inhibitor In Previously Treated Metastatic Renal Cell Carcinoma Benzinga

Jan 4, 2022

04:05PM EST Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022 Business Wire

08:24AM EST Exelixis Appoints Vicki L. Goodman, M.D., As Executive Vice President, Product Development & Medical Affairs And Chief Medical Officer Benzinga

Dec 23, 2021

07:29AM EST The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review Benzinga

Dec 17, 2021

08:00AM EST Exelixis Elects Jacqueline Wright to Its Board of Directors Business Wire

Dec 15, 2021

08:20AM EST Exelixis Initiates Phase 1b Trial Evaluating XL092 - Immuno-oncology Therapies On Advanced Solid Tumors RTTNews

08:03AM EST Exelixis Announces Initiation Of Phase 1b Trial Evaluating XL092 In Combination With Immuno-oncology Therapies In Patients With Advanced Solid Tumors Benzinga

Dec 14, 2021

06:12AM EST Exelixis Granted U.S. Patent #11,198,731 'Combinations of cabozantinib and atezolizumab to treat cancer' Benzinga

Nov 20, 2021

06:00AM EST Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021 Business Wire

Nov 9, 2021

11:41AM EST Exelixis Announces Enrollment Completion In Phase 3 CONTACT-01 Pivotal Trial Of Cabozantinib In Combination With Immune Checkpoint Inhibitor In Previously Treated Metastatic Non-Small Cell Lung Cancer Benzinga

11:41AM EST CORRECTION: Exelixis Reported Q3 Earnings Nov. 2 Benzinga

11:41AM EST Exelixis Q3 Adj. EPS $0.20 Beats $0.16 Estimate, Sales $328.42M Miss $354.02M Estimate Benzinga

08:00AM EST Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer Business Wire

Nov 3, 2021

04:06PM EDT Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December Business Wire

12:44PM EDT Analyst Ratings For Exelixis Benzinga

09:20AM EDT RBC Capital Maintains Outperform on Exelixis, Lowers Price Target to $31 Benzinga

09:19AM EDT The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering Benzinga

09:14AM EDT HC Wainwright & Co. Maintains Buy on Exelixis, Lowers Price Target to $52 Benzinga

Nov 2, 2021

05:34PM EDT Exelixis Sees FY21 Sales $1.30B-$1.35B Vs. $1.39B Est. Benzinga

05:31PM EDT Exelixis Q3 EPS $0.20 Beats $0.16 Estimate, Sales $328.42M Miss $354.02M Estimate Benzinga

05:30PM EDT Exelixis: Q3 Earnings Insights Benzinga

04:06PM EDT Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update Business Wire

11:49AM EDT Exelixis Earnings Perspective: Return On Capital Employed Benzinga

10:54AM EDT Oppenheimer Maintains Outperform on Exelixis, Lowers Price Target to $29 Benzinga

10:54AM EDT The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US Benzinga

10:41AM EDT Earnings Scheduled For November 2, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 19, 2021

04:05PM EDT Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021 Business Wire

Oct 14, 2021

08:31AM EDT Exelixis, STORM Therapeutics Enter Into Exclusive Collaboration, License Agreement To 'Discover And Develop Inhibitors Of Novel RNA Modifying Enzymes' Benzinga

08:16AM EDT Exelixis Inc. (EXEL) said it has reached an exclusive collaboration and license agreement with STORM Therapeutics. They will discover and advance novel drug leads intended for the treatment of cancer. RTTNews

08:04AM EDT Exelixis And STORM Enter Into Agreement To Discover And Develop Inhibitors Of Novel RNA Modifying Enzymes RTTNews

08:00AM EDT Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes Business Wire

08:00AM EDT Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin's Lymphoma Business Wire

Oct 7, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 Benzinga

05:02AM EDT Jefferies Initiates Coverage On Exelixis with Buy Rating, Announces Price Target of $28 Benzinga

Sep 20, 2021

11:31AM EDT Exelixis Highlights Presentation Of Final Results From Phase 3 COSMIC-311 Pivotal Trial Of CABOMETYX In Patients With Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer At ESMO 2021 Benzinga

11:30AM EDT Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX(r) in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021 Business Wire

08:10AM EDT A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 2% Benzinga

07:49AM EDT Truist Securities Maintains Buy on Exelixis, Lowers Price Target to $36 Benzinga

06:02AM EDT A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 2% Benzinga

Sep 18, 2021

10:31AM EDT Exelixis Inc. (EXEL) said that it presented detailed results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib or CABOMETYX in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer or CRPC at the 2021 European Society of Medical Oncology or ESMO Congress. RTTNews

07:30AM EDT Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021 Business Wire

12:11AM EDT FDA Approves Exelixis' Cabometyx To Treat Metastatic RTTNews

Sep 17, 2021

04:26PM EDT Exelixis Announces U.S. FDA Approval Of CABOMETYX (cabozantinib) For Patients With Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Benzinga

Sep 16, 2021

07:51AM EDT Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery Benzinga

03:30AM EDT Exelixis Reports Positive Data From Post-hoc Exploratory RTTNews

03:03AM EDT Exelixis : CABOMETYX- OPDIVO Valuable Treatment Option That Improves Outcomes For Advanced Kidney Cancer Patients RTTNews

02:30AM EDT Exelixis Announces CABOMETYX(r) in Combination with OPDIVO(r) Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021 Business Wire

Sep 6, 2021

11:32PM EDT Exelixis Inc. (EXEL) announced that Gisela Schwab, the company's President, Product Development and Medical Affairs and Chief Medical Officer, passed away over the weekend. Schwab had been on a medical leave of absence since June 18, 2021. Gisela joined Exelixis in September 2006. RTTNews

01:00PM EDT Exelixis Statement on the Passing of Two Senior Executives Business Wire

Sep 1, 2021

04:05PM EDT Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September Business Wire

Aug 26, 2021

07:52AM EDT Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer Benzinga

Aug 25, 2021

04:14PM EDT Exelixis Announces Partner Takeda And Ono Receive Approval In Japan For CABOMETYX In Combination With OPDIVO For The Treatment Of Unresectable Or Metastatic Renal Cell Carcinoma Benzinga

04:05PM EDT Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX(r) (cabozantinib) in Combination with OPDIVO(r) (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma Business Wire

Aug 16, 2021

03:47PM EDT Exelixis, Invenra Expand Oncology Pact Benzinga

08:14AM EDT Exelixis, Invenra Announce Expanded Collaboration - Quick RTTNews

08:11AM EDT Exelixis And Invenra Expand Collaboration To Discover And Develop Novel Biologics In Oncology Benzinga

08:08AM EDT Exelixis And Invenra Expand Discovery And Licensing Collaboration To Include Additional 20 Oncology Targets RTTNews

08:05AM EDT Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology Business Wire

Aug 5, 2021

06:01PM EDT Recap: Exelixis Q2 Earnings Benzinga

05:56PM EDT Exelixis Q2 Adj. EPS $0.37 Beats $0.07 Estimate, Sales $385.18M Beat $298.16M Estimate; Raises FY21 Sales Guidance To $1.3B-$1.4B vs $1.23B Est. Benzinga

04:06PM EDT Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update Business Wire

03:13PM EDT Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid Cancer Benzinga

08:24AM EDT Exelixis Announces U.S. FDA Accepts For Priority Review The Supplemental New Drug Application For CABOMETYX For Patients With Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Benzinga

08:13AM EDT Exelixis : FDA Accepts For Priority Review SNDA Of CABOMETYX For Thyroid Cancer RTTNews

08:00AM EDT Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX(r) (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Business Wire

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 22, 2021

04:05PM EDT Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021 Business Wire

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

04:05PM EDT Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021 Business Wire

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jun 30, 2021

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 29, 2021

08:17AM EDT The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout Benzinga

Jun 28, 2021

02:40PM EDT Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher Benzinga

12:22PM EDT Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump Benzinga

11:16AM EDT Needham Maintains Buy on Exelixis, Lowers Price Target to $30 Benzinga

05:41AM EDT Exelixis and Ipsen Announced Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer Benzinga

Jun 25, 2021

11:50AM EDT Exelixis Option Alert: Jul 16 $23 Calls at the Ask: 4200 @ $0.8 vs 278 OI; Earnings 8/5 After Close [est] Ref=$22.92 Benzinga

Jun 21, 2021

05:24PM EDT Exelixis 8-K Shows. Co. Received Notice Letters From Teva Related To Abbreviated New Drug Application For CABOMETYX Tablets; Co. Filed Complaint In US For Patent Infringement Against Teva Benzinga

Jun 18, 2021

08:05AM EDT Exelixis Chief Medical Officer Gisela Schwab To Take Medical Leave Of Absence RTTNews

08:02AM EDT Exelixis Reports Chief Medical Officer To Take Medical Leave Of Absence Benzinga

08:00AM EDT Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence Business Wire

Jun 15, 2021

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 Benzinga

06:07AM EDT HC Wainwright & Co. Initiates Coverage On Exelixis with Buy Rating, Announces Price Target of $47 Benzinga

Jun 14, 2021

08:34AM EDT Exelixis Inc. (EXEL) said Monday that it has reached a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Co. (BMY) for STELLAR-002, a new phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced solid tumors. RTTNews

08:14AM EDT Exelixis Announces Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb For STELLAR-002 RTTNews

08:01AM EDT Exelixis Announces Clinical Trial Collaboration with Bristol Meyers Squibb to Evaluate XL092 for Advanced Solid Tumors. Benzinga

08:00AM EDT Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors Business Wire

Jun 7, 2021

08:03AM EDT Exelixis And Ipsen Highlight Presentation Of Results From Phase 3 COSMIC-311 Pivotal Trial Of Cabozantinib At ASCO 2021 Benzinga

08:00AM EDT Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021 Business Wire

Jun 4, 2021

09:01AM EDT Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated In Analysis Of Phase 3 CheckMate -9ER Trial Of CABOMETYX (cabozantinib) In Combination With OPDIVO (nivolumab) In Patients With Previously Untreated Advanced Renal Cell Carcinoma Benzinga

09:00AM EDT Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX(r) (cabozantinib) in Combination with OPDIVO(r) (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma Business Wire

09:00AM EDT Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX(r) (cabozantinib) in Combination with OPDIVO(r) (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma Business Wire

09:00AM EDT Exelixis Announces Positive Phase 2 Results for CABOMETYX(r) (cabozantinib) in Combination with OPDIVO(r) (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021 Business Wire

May 26, 2021

04:16PM EDT Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June Business Wire

May 25, 2021

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

07:50AM EDT Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients Benzinga

May 24, 2021

04:05PM EDT Exelixis Announces Phase 1b Results From Cohort 6 Of COSMIC-021 Trial In Patients With Metastatic Castration-Resistant Prostate Cancer Benzinga

May 6, 2021

04:53PM EDT Exelixis: Q1 Earnings Insights Benzinga

04:53PM EDT Exelixis Sees FY21 Revs $1.15B-$1.25B Vs $1.22B Est Benzinga

04:50PM EDT Exelixis Q1 EPS $0.09 Beats $0.03 Estimate, Sales $270.23M Beat $265.94M Estimate Benzinga

04:07PM EDT Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update Business Wire

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 4, 2021

08:03AM EDT Exelixis Says Expands Biotherapeutics Porfolio With Acquisition Of GamaMabs Pharma's Hmanized Antibody Program Against A Novel Oncology Target; Terms Not Disclosed Benzinga

08:00AM EDT Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma's First-in-Class Humanized Antibody Program Against a Novel Oncology Target Business Wire

Apr 27, 2021

04:05PM EDT Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May Business Wire

Apr 22, 2021

04:05PM EDT Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021 Business Wire

Apr 19, 2021

10:33AM EDT Morgan Stanley Maintains Equal-Weight on Exelixis, Lowers Price Target to $26 Benzinga

Apr 15, 2021

07:49AM EDT The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split Benzinga

Apr 5, 2021

08:23AM EDT Biotechnology company Exelixis, Inc. (EXEL) announced Monday that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of XB002 in patients with advanced solid tumors. RTTNews

08:14AM EDT Exelixis : FDA Accepts IND For XB002 In Patients With Advanced Solid Tumors RTTNews

08:02AM EDT Exelixis Announces US FDA Accepts Investigational New Drug Application For XB002 In Patients With Advanced Solid Tumors; Says Phase 1 Clinical Trial Expected To Begin In Q2 2021 Benzinga

08:00AM EDT Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors Business Wire

Apr 1, 2021

12:04PM EDT Royalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK Benzinga

Mar 31, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021 Benzinga

07:41AM EDT The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO Benzinga

07:11AM EDT Credit Suisse Initiates Coverage On Exelixis with Outperform Rating, Announces Price Target of $30 Benzinga

01:01AM EDT Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX(r) (cabozantinib) in Combination with OPDIVO(r) (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma Business Wire

Mar 30, 2021

08:21AM EDT Exelixis Announces Enrollment Completion In Phase 3 COSMIC-313 Pivotal Trial Of Cabozantinib In Combination With Nivolumab And Ipilimumab Versus Nivolumab And Ipilimumab In Previously Untreated Advanced Renal Cell Carcinoma Benzinga

08:16AM EDT Exelixis Announces Enrollment Completion In Phase 3 COSMIC-313 Pivotal Trial RTTNews

08:00AM EDT Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma Business Wire

Mar 18, 2021

09:10AM EDT Exelixis' XL092 To Be Tested In Combination With Bavencio In Urothelial Carcinoma Benzinga

08:14AM EDT Exelixis Enters Clinical Trial Collaboration And Supply Agreement With Merck KGaA And Pfizer RTTNews

08:02AM EDT Exelixis Announces Clinical Trial Collaboration And Supply Agreement With Merck KGaA, Darmstadt, Germany And Pfizer To Evaluate XL092 And Avelumab In Various Forms Of Locally Advanced Or Metastatic Urothelial Carcinoma; Financial Details Not Disclosed Benzinga

08:00AM EDT Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma Business Wire

Mar 12, 2021

08:59AM EST Wolfe Research Initiates Coverage On Exelixis with Outperform Rating, Announces Price Target of $35 Benzinga

Mar 8, 2021

08:52AM EST Exelixis In License Deal With WuXi Biologics To Support Further Expansion Of Growing Oncology Biologics Pipeline RTTNews

08:46AM EST Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline Business Wire

Feb 26, 2021

12:55PM EST European Medicines Agency's CHMP Backs Approval Of Cabometyx/Opdivo Combo In Kidney Cancer Benzinga

07:15AM EST Exelixis' Partner Ipsen Gets Positive CHMP Opinion For CABOMETYX- OPDIVO Combination For Advanced Renal Cell Carcinoma RTTNews

06:30AM EST Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX(r) (cabozantinib) in Combination with OPDIVO(r) (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma Business Wire

Feb 25, 2021

04:24PM EST Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March Business Wire

11:11AM EST Exelixis' Cabozantinib Gets Breakthrough Therapy Status In Differentiated Thyroid Cancer Benzinga

08:25AM EST Exelixis Reports Breakthrough Therapy Designation Granted To Cabozantinib For Treatment Of Patients With Previously-Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Benzinga

08:00AM EST Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Business Wire

Feb 19, 2021

04:07PM EST Exelixis to Webcast Virtual Fireside Chat as Part of the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021 Business Wire

Feb 16, 2021

09:19AM EST Piper Sandler Maintains Overweight on Exelixis, Raises Price Target to $36 Benzinga

09:06AM EST Exelixis' Cabozantinib Shows Overall Objective Response Rates of 38% In Genitourinary Tumor Settings Benzinga

09:01AM EST Exelixis' Cabozantinib Data Shows Clinically Significant Benefit Versus Pfizer's Sutent, In A Type Of Kidney Cancer Benzinga

Feb 13, 2021

01:00PM EST Exelixis Highlights Positive Results for CABOMETYX(r) (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU Business Wire

Feb 12, 2021

05:15PM EST Exelixis Announces Final Phase 1 Results from Clinical Trial Sponsored by the National Cancer Institute at ASCO GU for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Patients with Refractory Metastatic Genitourinary Tumors Business Wire

Feb 11, 2021

10:34AM EST Exelixis shares were trading higher after the company reported better-than-expected Q4 EPS and sales results. The company also issued FY21 sales guidance above analyst estimates. Benzinga

Feb 10, 2021

04:40PM EST Recap: Exelixis Q4 Earnings Benzinga

04:11PM EST Exelixis Sees FY21 Sales $1.15B-$1.25B vs $1.2B Estimate Benzinga

04:10PM EST Exelixis Q4 Adj. EPS $0.14 Beats $0.05 Estimate, Sales $270.10M Beat $262.14M Estimate Benzinga

04:05PM EST Exelixis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Business Wire

03:57PM EST Notable After-Hours Earnings For Wednesday, Feb. 10, 2021 And Expected Report Times: CERN, RDFN, IRBT, PACB, KERN, TRUP, ATUS, SONO, ZG, ZNGA, PAYC, QUOT, UBER, SAVE, SSNC, MOH, CXW, MGM, ORLY, EFX, KGC, EXEL, PPC Benzinga

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

03:43AM EST Earnings Scheduled For February 10, 2021 Benzinga

Feb 9, 2021

04:08PM EST Exelixis to Host Investor Briefing to Discuss Data Presented at the American Society of Clinical Oncology's 2021 Genitourinary Cancers Symposium Business Wire

10:16AM EST Earnings Outlook For Exelixis Benzinga

07:13AM EST Opdivo Plus Cabometyx Combo Shows Superior Clinical Benefit Versus Sunitinib In Late-Stage Kidney Cancer Study Benzinga

Feb 8, 2021

05:01PM EST Bristol Myers, Exelixis Report Results From Analyses Of Phase 3 CheckMate -9ER Trial That Showed 'clinically meaningful, sustained efficacy benefits as well as quality of life improvements with the combination of OPDIVO, CABOMETYX...' Benzinga

05:00PM EST Exelixis Announces Positive Findings at ASCO GU for CABOMETYX(r) (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma Business Wire

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Feb 4, 2021

04:06PM EST Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 11, 2021 Business Wire

Feb 1, 2021

08:01AM EST Exelixis, Adagene Enter Into Collaboration, License Agreement To Develop Novel Masked Antibody-Drug Conjugate Therapies With Improved Safety, Efficacy Profiles Benzinga

08:00AM EST Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles Business Wire

Jan 27, 2021

04:05PM EST Exelixis to Release Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 10, 2021 Business Wire

Jan 25, 2021

08:15AM EST Exelixis Announces Initiation Of First-in-human Phase 1 Trial Evaluating XL102 RTTNews

08:01AM EST Exelixis Reports Initiation Of Phase 1 Trial Evaluating XL102 As Single Agent and in Combination with Other Anti-Cancer Agents in Patients with Advanced or Metastatic Solid Tumors Benzinga

08:00AM EST Exelixis Announces Initiation of Phase 1 Trial Evaluating XL102 as a Single Agent and in Combination with Other Anti-Cancer Agents in Patients with Advanced or Metastatic Solid Tumors Business Wire

Jan 22, 2021

01:11PM EST Exelixis Announces FDA Approval Of CABOMETYX In Combination With OPDIVO As First-Line Treatment For Patients With Advanced Renal Cell Carcinoma Benzinga

01:10PM EST Exelixis Announces U.S. FDA Approval of CABOMETYX(r) (cabozantinib) in Combination with OPDIVO(r) (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma Business Wire

Jan 10, 2021

04:00PM EST Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021 Business Wire

Jan 4, 2021

04:05PM EST Exelixis to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021 Business Wire

Dec 21, 2020

07:33AM EST Exelixis Says its Phase 3 Trial of COSMIC-311 Met its Co-Primary Endpoint Benzinga

07:30AM EST Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer Business Wire

Dec 16, 2020

12:37PM EST Morgan Stanley Maintains Equal-Weight on Exelixis, Lowers Price Target to $27 Benzinga

08:00AM EST XWPharma Ltd. today announced thatMichael M. Morrissey, Ph.D.has been appointed to the companys Board of Directors.Dr. Morrisseybrings extensive experience as a scientist, leader of highly productive Research and Development organizations, and chief executive officer of a fully-integrated, widely respected biopharma company. GlobeNewswire Inc

Dec 7, 2020

08:31AM EST Exelixis Exercises Exclusive Option For Aurigene's Novel CDK7 Inhibitor RTTNews

08:06AM EST Exelixis In-licenses Aurigene's Novel CDk7 Inhibitor, Files Investigational New Drug Application For Phase 1 Clinical Trial In Advanced Solid Tumors Benzinga

Dec 2, 2020

08:00AM EST Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application Business Wire

Nov 27, 2020

08:20AM EST Exelixis, Inc. (EXEL) said Friday that Takeda Pharmaceutical Co. Limited (TKPHF.PK, TAK) has received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market Cabometyx (cabozantinib) as a treatment for patients with unresectable hepatocellular carcinoma (HCC) that has progressed after prior systemic therapy. RTTNews

08:04AM EST Exelixis: Takeda Receives Approval In Japan For CABOMETYX RTTNews

08:02AM EST Exelixis Reports Partner Takeda Receives Approval In Japan For CABOMETYX For Treatment Of Unresectable Hepatocellular Carcnioma Benzinga

08:00AM EST Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX(r) (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy Business Wire

Nov 23, 2020

05:30PM EST Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December Business Wire

Nov 5, 2020

05:07PM EST Exelixis Sees FY20 Sales $900M-$950M Vs $922M Estimates Benzinga

05:06PM EST Exelixis Q3 EPS $0.04 Beats $0.01 Estimate, Sales $231.10M Beat $215.49M Estimate Benzinga

04:06PM EST Exelixis Announces Third Quarter 2020 Financial Results and Provides Corporate Update Business Wire

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

04:05PM EST Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November Business Wire

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 27, 2020

08:25AM EDT The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga

01:10AM EDT Exelixis Announces Takeda And Ono Submit Supplemental Application For CABOMETYX In Combination With OPDIVO RTTNews

01:02AM EDT Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX(r) (cabozantinib) in Combination with OPDIVO(r) (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan Business Wire

Oct 26, 2020

10:21AM EDT Stifel Maintains Hold on Exelixis, Raises Price Target to $27 Benzinga

08:14AM EDT Exelixis: First Patient Enrolled In Phase 1 Trial Cohort Evaluating XL092 In Combination With Atezolizumab RTTNews

08:07AM EDT Exelixis Announces First Patient Enrolled In Phase 1 Trial Cohort Evaluating XL092 In Combination With Atezolizumab In Patients With Advanced Solid Tumors Benzinga

Oct 22, 2020

04:05PM EDT Exelixis to Release Third Quarter 2020 Financial Results on Thursday, November 5, 2020 Business Wire

Oct 19, 2020

07:01AM EDT Bristol Myers Squibb and Exelixis, Inc. Announce The FDA Has Accepted for Priority Review Applications for OPDIVO in Combination with CABOMETYX in Advanced Renal Cell Carcinoma Benzinga

Oct 9, 2020

03:02AM EDT Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor Business Wire

03:01AM EDT Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor Business Wire

Sep 22, 2020

08:16AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

07:38AM EDT Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $29 Benzinga

Sep 21, 2020

10:25AM EDT Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts Of COSMIC-021 Trial Of Cabozantinib/Atezolizum RTTNews

10:21AM EDT Exelixis Highlights Results From 2 Renal Cell Carcinoma Cohorts Of COSMIC-021 Trial Of Cabozantinib In Combo With Atezolizumab Benzinga

10:20AM EDT Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab Business Wire

09:31AM EDT Piper Sandler Maintains Overweight on Exelixis, Raises Price Target to $33 Benzinga

09:04AM EDT Oppenheimer Maintains Outperform on Exelixis, Raises Price Target to $37 Benzinga

Sep 15, 2020

08:09AM EDT Exelixis and Iconic Therapeutics Announce Preclinical Data That 'Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors' Benzinga

08:00AM EDT Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors Business Wire

Sep 14, 2020

08:00AM EDT Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020 Business Wire

Sep 8, 2020

04:05PM EDT Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September Business Wire

08:05AM EDT Exelixis And Catalent Biologics Enter Into Collaboration, License, And Exclusive Option Agreement To Develop Antibody-Drug Conjugates Leveraging SMARTag Bioconjugation Technology Benzinga

08:05AM EDT Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer Business Wire

08:01AM EDT Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag(r) Bioconjugation Technology Business Wire

Aug 24, 2020

08:09AM EDT Exelixis Announces Submission Of SNDA For CABOMETYX In Combination With Opdivo For Advanced Renal Cell Carcinoma RTTNews

08:08AM EDT Exelixis Announces Submission of Supplemental New Drug Application to US FDA for CABOMETYX in Combination With Opdivo for Advanced Renal Cell Carcinoma Benzinga

08:00AM EDT Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX(r) (cabozantinib) in Combination With Opdivo(r) (nivolumab) for Advanced Renal Cell Carcinoma Business Wire

Aug 7, 2020

09:38AM EDT Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $23 Benzinga

Aug 6, 2020

05:11PM EDT Exelixis Sees FY20 Sales $900M-$950M Vs. $908.87M Est. Benzinga

05:11PM EDT Exelixis Q2 EPS $0.25 Beats $0.12 Estimate, Sales $259.50M Beat $226.36M Estimate Benzinga

04:06PM EDT Exelixis Announces Second Quarter 2020 Financial Results and Provides Corporate Update Business Wire

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Jul 29, 2020

04:05PM EDT Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020 Business Wire

Jul 20, 2020

08:13AM EDT Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma Benzinga

08:10AM EDT Exelixis Begins CONTACT-03 Phase 3 Pivotal Trial Of Cabozantinib In Combination With Atezolizumab RTTNews

08:00AM EDT Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma Business Wire

Jul 15, 2020

10:20AM EDT Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $22 Benzinga

document.getElementById("sgxS1l").onerror = function(){this.style.display='none';}; .dark-mode .zq0VdY{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .zq0VdY{ color: #333333; background-color: white; border: 2px solid #333333; }EXELExelixis Incstock NASDAQ

EXEL
Exelixis Inc
stock NASDAQ